Summary
| CA ID | CA-H001 · HEALTH DOMAIN |
| Target | Health Canada · TGA (Australia) · Provincial Health Authorities |
| Claim Type | Negligent failure to diagnose · Systemic denial of established disease |
| Jurisdictions | Canada (ON, BC, AU federal) · Australia (federal + state) |
| Class Threshold | 30+ patients with: positive PCR/serology + symptom match + official denial |
| Current Status | BUILDING — rain cheques accumulating. GREYBACK tracking patient count. |
| Pool Estimate | Systemic — no cap. AU DOH alone: 20+ years of denial, thousands of patients. |
| CLO | Amani Joffe — GC EOSE Labs + GC Scarborough Transit Connect |
N6 Kill Chain
N1 World
N2 Eligibility
N3 CLO Brief
N4 Evidence
N5 File/Join
N6 Settled
N1 — World Model: Borrelia burgdorferi confirmed in Canadian + Australian ticks. NP-LYME-001 through NP-LYME-008 mapped.
N2 — Eligibility: Individual patients with positive PCR + documented denial qualify. Pattern claim at 3+. Class at 30+.
N3 — CLO Brief: Amani has reviewed disease mechanics. Brief needs: patient count, jurisdiction breakdown, denial letter corpus.
N4 — Evidence: AU DOH official position on file ("Lyme does not occur in Australia"). VLA15 block documented. Rain cheques accumulating.
N5 — File/Join: Pending 30-patient threshold. 1 confirmed. ~29 to go.
N6 — Settled: Proceeds → feedles.ca trust.
N2 — Eligibility: Individual patients with positive PCR + documented denial qualify. Pattern claim at 3+. Class at 30+.
N3 — CLO Brief: Amani has reviewed disease mechanics. Brief needs: patient count, jurisdiction breakdown, denial letter corpus.
N4 — Evidence: AU DOH official position on file ("Lyme does not occur in Australia"). VLA15 block documented. Rain cheques accumulating.
N5 — File/Join: Pending 30-patient threshold. 1 confirmed. ~29 to go.
N6 — Settled: Proceeds → feedles.ca trust.
Disease Mechanics (NP References)
· NP-LYME-001: Spirochete = helical drilling machine. OspC/VlsE surface rotation evades antibodies.
· NP-LYME-002: Biofilm dormancy — antibiotics need active division. Standard 4-week course misses dormant cells.
· NP-LYME-003: Two-tier serology = 30-50% false negative in early Lyme. Negative result is not diagnostic.
· NP-LYME-004: PTLDS = 3 distinct mechanisms conflated as one condition. Type 1/2/CNS require different protocols.
· NP-LYME-005: Babesiosis co-infection missed by standard protocol — never tested alongside Lyme in AU/CA.
· NP-LYME-006: VLA15 vaccine — EU approved 2024, 79% efficacy, blocked AU/CA without stated reason. Regulatory capture.
· NP-LYME-007: AU DOH official position: "Lyme disease does not occur in Australia." Contradicted by published evidence (2016+).
· NP-LYME-008: IDSA 2006 guidelines cited by insurers after 2020 revision. Bad faith denial pattern.
Legal Strategy
Phase 1 — Individual claims: Document each qualifying patient (positive PCR + symptoms + denial letter). File individual negligence claims. Each = rain cheque.
Phase 2 — Pattern detection: When 3+ share identical fact pattern → pattern claim. Establishes systemic nature.
Phase 3 — Class certification: 30+ → class action. CBA registry for precedent. Provincial courts AU/CA.
Phase 4 — Sovereign enforcement: If DOH will not revise → ICJ / UN Special Rapporteur on Health. VLA15 block = strongest angle.
GREYBACK role: Yang case builder — builds the evidentiary record, the denial corpus, the patient count. TAZ inverts at floor = accountability.
Phase 2 — Pattern detection: When 3+ share identical fact pattern → pattern claim. Establishes systemic nature.
Phase 3 — Class certification: 30+ → class action. CBA registry for precedent. Provincial courts AU/CA.
Phase 4 — Sovereign enforcement: If DOH will not revise → ICJ / UN Special Rapporteur on Health. VLA15 block = strongest angle.
GREYBACK role: Yang case builder — builds the evidentiary record, the denial corpus, the patient count. TAZ inverts at floor = accountability.
⚠️ VERIFY-PATIENT-FIRST — same doctrine as VERIFY-FIRST in SSAF. Read the actual medical record before writing any brief. No assumptions. IDSA 2006 vs 2020 distinction is the legal crux — confirm which version the insurer/DOH cited in each denial.
γ₁ = 14.134725141734693 · CA-H001 · Day 89 · EOSE Labs Inc.